These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 19954722)

  • 1. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage.
    Bomback AS; Muskala P; Bald E; Chwatko G; Nowicki M
    Clin Nephrol; 2009 Dec; 72(6):449-56. PubMed ID: 19954722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
    Mehdi UF; Adams-Huet B; Raskin P; Vega GL; Toto RD
    J Am Soc Nephrol; 2009 Dec; 20(12):2641-50. PubMed ID: 19926893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors.
    Davidson MB; Wong A; Hamrahian AH; Stevens M; Siraj ES
    Endocr Pract; 2008 Nov; 14(8):985-92. PubMed ID: 19095597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients.
    Guasti L; Gaudio G; Lupi A; D'Avino M; Sala C; Mugellini A; Vulpis V; Felis S; Sarzani R; Vanasia M; Maffioli P; Derosa G
    Drug Des Devel Ther; 2017; 11():2293-2300. PubMed ID: 28831241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Spironolactone reduces blood pressure and albuminuria of obese hypertensive patients with metabolic syndrome].
    Ezequiel DG; Paula RB; Lovisi JC; Bicalho TC; Souza Fillho SF; Rezende Sde P; Costa MB
    J Bras Nefrol; 2013; 35(1):69-72. PubMed ID: 23598755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
    Sato A; Suzuki Y; Saruta T
    Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
    Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist.
    Sato A; Fukuda S
    Hypertens Res; 2013 Oct; 36(10):879-84. PubMed ID: 23864056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
    Ando K; Ohtsu H; Arakawa Y; Kubota K; Yamaguchi T; Nagase M; Yamada A; Fujita T;
    Hypertens Res; 2010 Jun; 33(6):616-21. PubMed ID: 20379190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N; Kalaitzidis R; Bakris GL
    Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of low-dose spironolactone in subjects with resistant hypertension.
    Nishizaka MK; Zaman MA; Calhoun DA
    Am J Hypertens; 2003 Nov; 16(11 Pt 1):925-30. PubMed ID: 14573330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial.
    Derosa G; Maffioli P; D'Avino M; Sala C; Mugellini A; Vulpis V; Felis S; Guasti L; Sarzani R; Bestetti A; Vanasia M; Gaudio G;
    Cardiovasc Ther; 2017 Feb; 35(1):47-54. PubMed ID: 27860389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
    Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
    Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose and very low-dose spironolactone in combination therapy for essential hypertension: evaluation by self-measurement of blood pressure at home.
    Hanazawa T; Obara T; Ogasawara K; Shinki T; Katada S; Inoue R; Metoki H; Asayama K; Kikuya M; Ohkubo T; Mano N; Imai Y
    Clin Exp Hypertens; 2011; 33(7):427-36. PubMed ID: 21777149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of effects of low dose of spironolactone and a thiazide diuretic in patients with hypertension treated with an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker.
    Yutaka M; Mifune M; Kubota E; Itoh H; Saito I
    Clin Exp Hypertens; 2009 Nov; 31(8):648-56. PubMed ID: 20001457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.